Effect of RANKL on Lower Depressive Symptoms In Hemodialysis Patients.

Area of Science:

• Nephrology
• Psychiatry
• Bone Metabolism

Background:

• Depression and osteoporosis are prevalent comorbidities in hemodialysis patients.
• Emerging evidence suggests a link between bone resorption pathways and depression.
• Specific anti-osteoporosis agents like denosumab and romosozumab target RANKL and may be suitable for dialysis patients.

Purpose of the Study:

• To investigate the association between depressive symptoms and levels of RANKL and OPG (Osteoprotegerin) in hemodialysis patients.
• To explore the potential role of RANKL and OPG in the manifestation of depression within this patient group.

Main Methods:

• A cross-sectional study involving 172 hemodialysis patients.
• Measurement of plasma RANKL, OPG, MMP-2, and MMP-9 levels.
• Logistic and linear regression analyses were used to assess the relationship between RANKL, OPG, and depressive symptoms (assessed by BDI score).

Main Results:

• Depressive symptoms were present in 52.3% of the participants.
• Higher plasma RANKL concentrations were significantly associated with lower BDI scores and reduced odds of depressive symptoms, even after multivariate adjustments.
• No significant association was found between OPG levels and depressive symptoms.

Conclusions:

• Elevated plasma RANKL levels are independently associated with a lower prevalence and severity of depressive symptoms in hemodialysis patients.
• These findings suggest a potential protective role of RANKL against depression in this population, warranting further investigation.
• The study highlights a potential link between bone metabolism and mental health in chronic kidney disease patients.